Keith Dredge – Vice President of Preclinical Development

Keith Dredge has 25 years’ experience in drug discovery and development projects, holding executive positions with Macrobiome Therapeutics, Zucero Therapeutics, ParagenBio, Progen Pharmaceuticals, TetraQ, and consulting with biotech companies in Australia, U.S. and Asia. Major achievements include leading the development of pixatimod from conception to Phase 2 clinical trials, supporting the nonclinical package for muparfostat for Phase 3 clinical testing, and devising early R&D testing for Celgene’s oncology portfolio, leading to the first publications of Revlimid® and Pomalyst®, now FDA-approved cancer medicines.

Keith has authored 50 scientific publications and is an inventor on two patent applications. Keith has a B.Sc. (Hons) in Toxicology and a PhD in Pharmacology from the National University of Ireland.